Edwards Lifesciences Corp. has signed a $100m deal to acquire CAS Medical Systems Inc., the developer of a non-invasive technology for measuring tissue oxygenation in the brain.
Under the terms of the agreement, Edwards will pay $2.45 per share of CAS’ common stock, a 56% premium to the company’s closing share price Feb. 11. The acquisition is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?